Formulation design of a highly hygroscopic drug (pyridostigmine bromide) for its hygroscopic character improvement and investigation of in vitro/in vivo dissolution properties

Drug Development and Industrial Pharmacy

Volumn 33, Issue 4, 2007, Pages 403-416

  Huang, Yuh Tyng ^a   Tsai, Tong Rong ^a   Cheng, Chun Jen ^a   Cham, Thau Ming ^a,d   Lai, Tsun Fwu ^b   Chuo, Wen Ho ^c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN INSTITUTE OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c TAJEN UNIVERSITY   (Taiwan)

^d NONE   (Taiwan)

Author keywords

23 full factorial design; Hygroscopic character; In vitro in vivo relationship; Sustained release pellets; Taguchi experimental design; Zero order mechanism

Indexed keywords

PYRIDOSTIGMINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COATING; DRUG DOSAGE FORM COMPARISON; DRUG PELLET; DRUG RELEASE; DRUG SOLUBILITY; FACTORIAL DESIGN; FRACTIONATION; IN VITRO STUDY; IN VIVO STUDY; LINEAR REGRESSION ANALYSIS; MALE; MOISTURE; NONHUMAN; RABBIT; SUSTAINED RELEASE PREPARATION; WATER ABSORPTION; WETTABILITY;

ABSORPTION; ANALYSIS OF VARIANCE; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CHOLINESTERASE INHIBITORS; DELAYED-ACTION PREPARATIONS; DRUG STABILITY; DRUG STORAGE; HUMIDITY; KINETICS; LINEAR MODELS; MALE; MICROSCOPY, ELECTRON, SCANNING; PYRIDOSTIGMINE BROMIDE; RABBITS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 34249309923     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040601031890     Document Type: Article

References (37)

1. Baert, L., & Remon, J. P. (1993). Influence of amount of granulation liquid on the drug release rate from pellets made by extrusion spheronisation. Int. J. Pharm., 95(1-3), 135-141.
2. Bechgaard, H., & Hegermann-Nielsen, G. (1978). Controlled release multiple units and single-unit doses. Drug Dev. Ind. Pharm., 4(1), 53-67.
3. Bodea, A., & Leucuta, S. E. (1997). Optimization of propranolol hydrochloride sustained release pellets using a factorial design. Int. J. Pharm., 154(1), 49-57.
4. Chariot, M., Francès, J., Lewis, G. A., Mathieu, D., Phan Tan Luu, R., & Stevens, H. N. E. (1987). A factorial approach to process variables of extrusion-spheronisation of wet powder masses. Drug Dev. Ind. Pharm., 13(9-11), 1639-1649.
5. Conine, J. W., & Hadley, H. R. (1970). Preparation of small solid pharmaceutical spheres. Drug Cosmet. Ind., 106(1), 38-41.
6. Dirnhuber, P., & Green, D. M. (1978). Effectiveness of Pyridostigmine in Reversing the Neuromuscular Blockade Produced by Soman. J. Pharm. Pharmacol., 30(7), 419-425.
7. Engineer, S., Shao, Z. J., & Khagani, N. A. (2004). Temperature/humidity sensitivity of sustained-release formulations containing Kollidon ® SR. Drug Dev. Ind. Pharm., 30(10), 1089-1094.
8. Gandhi, R., Kaul, C. L., & Panchagnula, R. (1999). Extrusion and spheronization in the development of oral controlled-release dosage forms. Pharm. Sci. Technol. Today., 2(1), 60-170.
9. Hegazy, N., Demirel, M., & Yazan, Y. (2002). Preparation and in vitro evaluation of pyridostigmine bromide microparticles. Int. J. Pharm., 242(1-2), 171-174.
10. Hileman, G. A., Goskonda, S. R., Spalitto, A. J., & Upadrashta, S. M. (1993). A factorial approach to high dose product development by an extrusion/spheronization process. Drug Dev. Ind. Pharm., 19(4), 483-491.
11. Huang, Y. B., Tsai, Y. H., Yang, W. C., Chang, J. S., Wu, P. C., & Takayama, K. (2004). Once-daily propranolol extended-release tablet dosage form: formulation design and in vitro/in vivo investigation. Eur. J. Pharm. Biopharm., 58(3), 607-614.
12. Kang, H. K., Bullman, T. A., Macfarlane, G. J., & Gray, G. C. (2002). Mortality among US and UK veterans of the Persian Gulf War: a review. Occup. Environ. Med., 59(12), 794-799.
13. Korsmeyer, R. W., Gurny, R., Doelker, E., Buri, P., & Peppas, N. A. (1983). Mechanisms of solute release from porous hydrophilic polymer. Int. J. Pharm., 15(1), 25-35.
14. Li, S., Lin, S., Daggy, B. P., Mirchandani, H. L., & Chien, Y. W. (2002). Effect of formulation variables on the floating properties of gastric floating drug delivery system. Drug Dev. Ind. Pharm., 28(7), 783-793.
15. Li, S., Lin, S., Daggy, B. P., Mirchandani, H. L., & Chien, Y. W. (2003). Effect of HPMC and Carbopol on the release and floating properties of gastric floating drug delivery system using factorial design. Int. J. Pharm., 253(1-2), 13-22.
16. Lin, A. Y., Muhammad, N. A., Pope, D., & Augsburger, L. L. (2003). A study of the effects of curing and storage conditions on controlled release diphenhydramine HCl pellets coated with Eudragit® NE30D. Pharm. Dev. Tech., 8(3), 277-287.
17. Lövgren, K., & Lundberg, P. J. (1989). Determination of sphericity of pellets prepared by extrusion/spheronization and the impact of some process parameters. Drug Dev. Ind. Pharm., 15(14-16), 2375-2392.
18. Martin, A., Bustamante, P., & Chun, A. (1993). Chapter 16 Micromeritics. In Physical Pharmacy ; Lea and Febiger; London; 423-452.
19. Michaelis, H. C. (1990). Determination of pyridostigmine plasma concentrations by high-performance liquid chromatography. J. Chromatogr., 534(1), 291-294.
20. Montgomery, D. C. (1996). Design and Analysis of Experiments; John Wiley & Sons: New York, NY.
21. 3 factorial design and the desirability function. Int. J. Pharm., 248(1-2), 51-60.
22. Peppas, N. A., & Sahlin, J. J. (1989). A simple equation for the description of solute release, III. Coupling of diffusion and relaxation. Int. J. Pharm., 57(2), 169-172.
23. Porter, S. C. (1997). Use of opadry, sureteric, and surelease for the aqueous film coating of pharmaceutical oral dosage forms. In Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms; McGinity, J. W., Ed.; Marcel Dekker, Inc.: New York; 327-372.
24. Qiu, Y., Cheskin, H. S., Engh, K. R., & Poska, R. P. (2003). Once-a-day controlled release dosage form of divalproex sodum I: formulation design and in vitro/in vivo investigations. J. Pharm. Sci., 92(6), 1166-1173.
25. Ragnarsoson, G., & Johansson, M. O. (1988). Coated drug cores in multiple unit preparation-Influence of particle size. Drug Dev. Ind. Pharm., 14(15-17), 2285-2297.
26. Rambali, B., Baert, L., Thonè, D., & Massart, D. L. (2001). Using experimental design to optimize the process parameters in fluidized bed granulation. Drug Dev. Ind. Pharm., 27(1), 47-55.
27. Reynold, A. D. (1970). A new technique for the production of spherical particles. Mfg. Chem. Aerosol. News., 41(1), 40-43.
28. Ritger, P. L., & Peppas, N. A. (1987a). A simple equation for description of solute release. I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinder or discs. J. Control. Release., 5(1), 23-36.
29. Ritger, P. L., & Peppas, N. A. (1987b). A simple equation for description of solute release. II. Fickian and anomalous release from swellable devices. J. Control. Release., 5(1), 37-42.
30. Roshdy, M. N., Schnaare, R. L., Sugita, E. T., & Schwartz, J. B. (2002). The effect of controlled release tablet performance and hydrogel strength on in vitro/in vivo correlation. Pharm. Dev. Tech., 7(2), 155-168.
31. Sidell, F. R. (1997). Nerve agents, Part I: Medical aspects of chemical and biological warfare. In The Textbooks of Military Medicine; Sidell, F. R., Takafuji, E. T., & Franz, D. R., Eds.; Office of the Surgeon General Department of the Army; Washington, D. C. USA. 129-179.
32. Takka, S., Sakr, A., & Goldberg, A. (2003). Development and validation of an in vitro-in vivo correlation for buspirone hydrochloride extended release tablets. J. Control. Release., 88(1), 147-157.
33. United States Food and Drug Administration (FDA). (1997). Guidance for industry, dissolution testing of IR solid oral dosage forms. United States Food and Drug Administration (FDA). (2003). FDA approves PB as pretreatment against nerve gas.
34. Vervaet, C., Baert, L., & Remon, J. P. (1995). Extrusion- spheronisation a literature review. Int. J. Pharm., 116(2), 131-146.
35. Wanger, J., & Nelson, E. (1964). Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J. Pharm. Sci., 53(11), 1392-1404.
36. Yang, S. C., & Zhu, J. B. (2002). Preparation and characterization of camptothecin solid lipid nanoparticles. Drug Dev. Ind. Pharm., 28(3), 265-274.
37. Zhang, G. H., Schwartz, J. B., & Schnaare, R. L. (1991). Bead coating. I. Change in release kinetics (and mechanism) due to coating levels. Pharm. Res., 8(3), 331-335.